Novartis Withdraws Its Application To Extend The Marketing Authorisationfor Zometa

The European Medicines Agency (EMEA) has been formally notified by
Novartis Pharma AG of its decision to withdraw the application to extend
the marketing authorisation to include a new indication for the
medicinal product Zometa (zoledronic acid).


Zometa was first authorised in the European Union in March 2001. It is
currently authorised for prevention of skeletal related events
(pathological fractures, spinal compression, radiation or surgery to
bone, or tumour-induced hypercalcaemia) in patients with advanced
malignancies involving bone, as well as for the treatment of
tumour-induced hypercalcaemia.


On 20 December 2006, Novartis Pharma submitted an application to extend
the currently authorised indications for Zometa to include prevention of
fracture and bone loss in postmenopausal women with early-stage breast
cancer treated with aromatase inhibitors. At the time of the withdrawal,
the application was under review by the Agency's Committee for Medicinal
Products for Human Use (CHMP).


In its official letter, the company stated that the withdrawal of the
application was based on the CHMP's consideration that the data provided
did not allow them to recommend authorisation of the extension of
indication.


Despite the company's decision to withdraw this application, Zometa
continues to be available in the currently approved indications.


More information about Zometa and the state of the scientific assessment
at the time of withdrawal of the new indication will be made available
in a question-and-answer document that will be published on the EMEA
website after the next meeting of the CHMP on 10-13 December 2007.


Notes:


1. Withdrawal of an application does not prejudice the possibility
of a company making a new application at a later stage.


2. More information about Zometa is available in the European
Public Assessment Report (EPAR):
click here.


emea.europa.eu


View drug information on Zometa.